Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Today’s reports address: How German prostate cancer specialists would treat themselves Identification of patients appropriate for focal therapy Italian management of men with an elevated PSA level Triple therapy for men with T3a,b disease
Filed under: Diagnosis, Management, Treatment | Tagged: bias, elevated PSA, focal therapy, Italy, T3 disease, training | Leave a Comment »
The following report gives core information on a fourth group of 15 papers that are being formally presented at ASCO.
Filed under: Uncategorized | Tagged: 2009, abstracts, ASCO | Leave a Comment »
The following report gives core information on a third group of 15 papers that are being formally presented at ASCO.
Filed under: Uncategorized | Tagged: ASCO 2009 abstracts | Leave a Comment »
The following abstracts of papers on prostate cancer are given in the abstract listings for the annual meeting of the American Society for Clinical Oncology (ASCO) as “publication only” abstracts but will not actually be presented at the meeting:
Filed under: Uncategorized | Tagged: 2009, abstracts, ASCO | 2 Comments »
The following report gives core information on a second group of 15 papers that are being formally presented at ASCO.
Filed under: Uncategorized | Tagged: ASCO 2009 abstracts | 1 Comment »
Today’s news reports cover such matters as: Genistein as a prostate cancer stimulating agent Molecular characterization of advanced prostate cancers Imaging technology and focal therapy
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: focal therapy, gene expression signature, genistein, imaging | Leave a Comment »
Over the next few days we plan to work our way through the abstracts for the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) , which were made available on line yesterday, and let you know what studies look to be of interest.
Filed under: Diagnosis, Drugs in development, Management, Prevention, Risk, Treatment | Tagged: abstracts, annual meeting, ASCO | Leave a Comment »
In today’s news reports we discuss: Genetic abnormalities and intermediate risk prostate cancer Ginger tablets to prevent chemotherapy-induced nausea Ixabebilone + mitoxantrone in patients after Taxotere
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: chemotherapy, expression, gene, ginger, intermediate, ixabepilone, mitoxantrone, nausea, risk | Leave a Comment »
“Liminality” and “biographical disruption” are not terms familiar to the average prostate cancer patient — unless perhaps that patient is a social anthropologist.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, event, limnal, transformative | Leave a Comment »
In an article to be published in Biosensors and Bioelectronics, the authors describe the development of an implantable sensor device which, they claim, has the potential to offer continuous cancer monitoring.
Filed under: Diagnosis, Risk | Leave a Comment »
FRET stands for “fluorescence resonance-energy transfer.” It’s a way to assess interactions between individual protein molecules, and allows researchers to find out how many receptors of specific types there are in a specific cancer specimen as well as how active those receptors are.
Filed under: Diagnosis, Risk, Uncategorized | Tagged: classification, FRET, pathology | Leave a Comment »
News reports today cover such issues as: Vitamin D and its possible role in development of prostate cancer Genetic testing among hereditary prostate cancer families Sex hormone levels and cognitive function in older men
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: cognitive function, epidemiology, estrogen, etiology, genetic testing, heredity, testosterobe, vitamin D | Leave a Comment »
We have just come across a retrospective analysis of a subset of patients originally enrolled in the RTOG 85-31 clinical trial and suggesting that patients who received ≤ 5 years of hormone therapy in association with radiation did worse clinically than those who received > 5 years of adjuvant hormone therapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, duration, homone therapy, radiation, RTOG 85-31 | Leave a Comment »
In what may become one of the landmark patent lawsuits of the 21st Century, a consortium of patients, pathologists, and researchers, with the support of the American Civil Liberties Union (the ACLU), has filed a lawsuit against Myriad Genetics and the U.S. Patent Office. They are challenging the right of the Patent Office to grant [...]
Filed under: Diagnosis, Risk | Tagged: gene, patent law, test | Leave a Comment »
This morning’s reports deal with: New Japanese guidelines on prostate cancer screening PCA3 — “from bench to bedside” Impact of hormonal therapy on bone mineral density and risk for fractures The initial results of the RENEW trial
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, BMD, bone mineral density, guidelines, Japan, PCA3, screening | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site